Invivo Education

Disclaimer: This information is provided for the use of physicians and other licensed health care practitioners only. This information is not for use by consumers. The information and or products are not intended for use by consumers or physicians as a means to cure, treat, prevent, diagnose or mitigate any disease or other medical condition. The information contained in this document is in no way to be taken as prescriptive nor to replace the physicians duty of care and personalised care practices.

Omega Quant Fatty Acid Testing
By Pippa Carey, BSc, BA Hons mBANT, CNHCreg

Today’s diet has drifted far from that of our ancestors creating nutrient gaps, deficiencies and imbalances that are potentially disease promoting. Fatty acids (FAs), in particular polyunsaturated fatty acids (PUFAs) omega-3 and 6, are one such group of nutrients where an imbalance appears to have developed. Omega-3 and 6 FAs must come from the diet and much of the shift in their balance could be blamed on over-consumption of omega-6-rich oils and processed foods, farmed meats and industrialised fats, like trans fats, coupled with under-consumption of wild, seasonal foods that naturally contain higher omega-3 levels. Insufficiencies and imbalances in FAs are thought to be critical for the healthy function of numerous body systems, including cardiovascular, neurological, immunological and inflammatory. With many of today’s chronic diseases having an inflammatory component and with research suggesting inflammatory responses are highly modifiable by altering levels and ratios of dietary fats, ‘knowing your fats’ becomes an important step on the road to achieving optimal health. 

Knowing your fats

From dietary fatty acids (saturated SFAs, monounsaturated MUFAs and PUFAs) the body produces more complex fat structures, such as triglycerides, cholesterol and phospholipids plus fatty acid derivatives like eicosanoids, all playing vital roles in numerous biochemical processes. The omega-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), found readily in oily fish, are widely associated with reducing risk factors for cardiovascular disease (CVD), dementia, certain cancers, diabetes and depression, plus influencing the inflammatory response and gene expression. Continued global research into the positive health effects of consuming MUFAs and PUFAs has meant a growing trend for foods like olive oil, salmon and sardines plus the use of dietary supplements such as evening primrose or fish oil. Whilst the weight of evidence in favour of benefits associated with these fats supports this increased consumption, our modern diets remain riddled with processed fats which are poorly handled by the body or with disproportionate amounts of essential fats that create unhealthy imbalances in overall FA status. Moreover, controversy continues to surround possible exposure to toxic contaminants, such as mercury, through high fish consumption and poor quality fish oil supplements. With all these confounding factors to consider, access to a test that assesses a client’s FA status at the outset of the clinical process offers a powerful tool to the practitioner wanting to bring about meaningful outcomes for the client.

Dr Harris

Omega Quant Full Fatty Acid Profile

Invivo Clinical, in partnership with OmegaQuant, recommend the Full Fatty Acid Profile which uses a simple blood spot sample and has a speedy turnaround time of 72 hours, but what sets this test apart from many others is the extensive reporting. Not only measuring omega-3, 6, 7 and 9 families of fatty acids and saturated fats but also expressing ratios of omega-3: omega-6, Arachidonic acid (AA): EPA and including blood levels of EPA and DHA using the Omega-3 index. The index is designed to report blood EPA and DHA levels as a percentage; 8% or more is believed to have cardio protective effects, whereas below 4% offers the least cardio protection. Furthermore, the report includes an inverse index for trans fats and lists of trans fat content of certain foods plus the EPA and DHA content of many fish and fish oil supplements.

Through research we are learning more about how different FAs interact with each other to modulate biochemical processes at cellular level and how by optimising and balancing dietary intake practitioners can individualise FA recommendations which support these processes.


Considerable research has focused on eicosanoids, the FA derivatives that, amongst their other functions, have strongly opposing effects on the body’s inflammatory responses being either pro-inflammatory or anti-inflammatory in their nature. Inflammation is a physiologically necessary process but is also a recognised component of many chronic diseases; eicosanoids have the capacity to modulate the intensity and duration of the inflammatory responses therefore controlling intake of eicosanoid precursors, namely FAs, is a potential route to influencing inflammation. Generally speaking, omega-6 AA-derived eicosanoids (series 2 prostaglandins) are considered pro-inflammatory (although exceptions are coming to light through further research) whereas omega-3 EPA and DHA-derived eicosanoids (series 3 prostaglandins) have opposing effects. Research suggests that by partially replacing AA in the cell phospholipid layer and altering constituents of the cell membrane in favour of omega-3 FAs, EPA and DHA could decrease production of AA-derived eicosanoids and in turn reduce inflammation. Moreover, the omega-3 and omega-6 pathways compete for the enzyme delta-6-desaturase, which has a greater affinity for omega-3 PUFAs so greater consumption could tip the balance in favour of a less inflammatory state. A wider understanding of the regulatory effects of EPA and DHA has come to light through research into their derivatives, resolvin and protectin, which are believed to regulate the inflammatory response, shutting off inflammation and limiting tissue damage. 

The omega-6 fatty acid, dihomogamma-linolenic (DGLA) is the precursor to another family of eicosanoids (series 1 prostaglandins) which have strong anti-inflammatory effects. DGLA derives from dietary linoleic acid (LA) and is the precursor to AA, but EPA is believed to inhibit the conversion of DGLA to AA so measuring levels of dietary EPA and DGLA, when trying to balance out the potential effects of AA, could prove clinically relevant. In addition, the body’s conversion rate of LA to AA is considered to be relatively inefficient so a reported high blood AA level might suggest the need to reduce consumption of AA rich foods, such as grain-fed meat, processed meats and non-organic eggs and concomitantly increase EPA and DHA rich foods such as oily fish to try to redress the balance. 

Understanding the client's baseline to navigate towards balance...

Balance is the key to the many benefits associated with the FAs and most particularly the ratios of dietary intake, in the case of omega-6: omega-3, 4:1 is widely considered an optimal ratio, but one that proves tricky to achieve. FA testing becomes clinically relevant when it provides an understanding of the client’s baseline status within the overall landscape of their daily diet. It reinforces recommendations, encourages greater client compliance and offers opportunities for evidence based practice. 

Invivo Clinical believes that the Full Fatty acid profile, with its extensive report, provides both practitioners and clients with a starting point from which to navigate towards balancing intakes of the highly beneficial FAs when faced with the vagaries of supplementation and a modern-day diet.

Omega 3 Webinar


Calder PC (2009) Biochemie, 91; 791-5 
Calder PC (2010) Nutrients, 2(3); 355-74 
Deckelbaum RJ, Torrejon C (2012) The Journal of Nutrition, 142;587S-591S 
Deckelbaum RJ, Worgall TS, Seo T (2006) American Journal of Clinical Nutrition,83 (suppl);1502S-5S
Engler MB et al. (2009) Circulation, 119(6);902-7 
Gillingham LG, Harris-Janz S, Jones PJ (2011) Lipids, 46(3);209-28 
Gribble MO et al. (2016) Journal of the Marine Biological Association of the United Kingdom, 96(1);43-59
Gruss TL ‘Fatty acid blood tests help assess risk for Heart disease’ Natural News, March 2008
Harris WS (2007) Pharmacological Research, 55(3);217-23
Harris WS, Von Schacky C (2004) Preventative Medicine, 39(1);212-20
Lin PY, et al. (2012) Journal of Clinical Psychiatry, 73(9);1245-54
Lopez S et al. (2016) Current Vascular Pharmacology, epub Jan 17 2016
Mozaffarian D (2009) International Journal of Environmental Research and Public Health, 6;1894- 1916
Nicolle L & A Beirne ‘Biochemical Imbalances in Disease’ 2010 Singing Dragon; London
Simopoulos AP (2002) Biomedicine & Pharmacotherapy, 56;365-79 
Vedin I et al. (2012) PLos ONE, 7(4);e35425

Invivo Education